MRE11 variants as predictive markers of radiotherapy response in muscle invasive bladder cancer

MRE11 variants as predictive markers of radiotherapy response in muscle invasive bladder cancer

Bibliographic Details
Main Authors:	Teo, M, Snowden, H, Elliott, F, Morgan, J, Harland, M, Taylor, G, Bishop, D, Kiltie, A
Format:	Journal article
Published:	2012

Similar Items

Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer
by: Teo, M, et al.
Published: (2014)

MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.
by: Choudhury, A, et al.
Published: (2010)

High MRE11 expression in muscle invasive bladder cancer is predictive of improved cause-specific survival following radical radiotherapy compared to surgery
by: Teo, T, et al.
Published: (2010)

MRE11 as a predictive biomarker of outcome following radiotherapy in bladder cancer
by: Walker, AK, et al.
Published: (2019)

Clinically relevant MRE11 variants in bladder cancer
by: Jevons, S
Published: (2015)

MRE11A isoform expression associated with outcome following radiotherapy in muscle-invasive bladder cancer does not alter cell survival and DNA double-strand break repair following ionising radiation
by: Walker, AK, et al.
Published: (2019)

Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
by: Choudhury, A, et al.
Published: (2011)

No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy
by: Walker, A, et al.
Published: (2017)

Utility of bladder-sparing therapy vs radical cystectomy for muscle-invasive bladder cancer
by: Efstathiou, J, et al.
Published: (2018)

A multicentre NCRI phase II study of hypofractionated conformal radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer
by: Choudhury, A, et al.
Published: (2010)

E3 ligase cIAP2 mediates downregulation of MRE11 and radiosensitization in response to HDAC inhibition in bladder cancer
by: Nicholson, J, et al.
Published: (2017)

Predictive biomarkers in muscle-invasive bladder cancer
by: Walker, A
Published: (2017)

High-throughput DNA sequencing identifies novel CtIP (RBBP8) variants in muscle-invasive bladder cancer patients
by: Jevons, S, et al.
Published: (2015)

Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future
by: Hermans, TJN, et al.
Published: (2017)

Analysis of variants in DNA damage signalling genes in bladder cancer
by: Choudhury, A, et al.
Published: (2008)

Contemporary patterns of multidisciplinary care in patients with muscle-invasive bladder cancer
by: Harshman, LC, et al.
Published: (2017)

Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network
by: Zuiverloon, TCM, et al.
Published: (2018)

The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes.
by: Teo, M, et al.
Published: (2012)

Mouse models of muscle-invasive bladder cancer: Key considerations for clinical translation based on molecular subtypes
by: Ruan, J, et al.
Published: (2018)

SPRTN protease-cleaved MRE11 decreases DNA repair and radiosensitises cancer cells
by: Na, J, et al.
Published: (2021)

In vitro functional effects of XPC gene rare variants from bladder cancer patients.
by: Qiao, B, et al.
Published: (2011)

Comparison of treatment outcome for radical surgery versus radical radiotherapy for invasive bladder cancer treated in a UK specialist treatment centre
by: Kotwal, S, et al.
Published: (2007)

Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center.
by: Kotwal, S, et al.
Published: (2008)

Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer
by: Ottley, EC, et al.
Published: (2020)

THE HYPOXIC REGULATION OF FGFR3 IN NON MUSCLE INVASIVE BLADDER CANCER
by: Blick, C, et al.
Published: (2011)

Ultrasound mediated gemcitabine delivery reduces the normal tissue toxicity of chemoradiation therapy in a muscle-invasive bladder cancer model
by: Ruan, J-L, et al.
Published: (2021)

Papillary and muscle invasive bladder tumors with distinct genomic stability profiles have different DNA repair fidelity and KU DNA-binding activities.
by: Bentley, J, et al.
Published: (2009)

Functional assays to determine the significance of two common XPC 3'UTR variants found in bladder cancer patients.
by: Qiao, B, et al.
Published: (2011)

The management of non-muscle-invasive bladder cancer: A comparison of European and UK guidelines
by: Leiblich, A, et al.
Published: (2018)

The impact of histological variants of urothelial carcinoma on clinical outcomes following trimodality bladder-sparing chemoradiation
by: Kiltie, A, et al.
Published: (2017)

The polyAT, intronic IVS11-6 and Lys939Gln XPC polymorphisms are not associated with transitional cell carcinoma of the bladder.
by: Sak, S, et al.
Published: (2005)

APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer.
by: Sak, S, et al.
Published: (2005)

High levels of patient satisfaction in joint uro-oncology clinics to assist patient choice in early prostate cancer and muscle-invasive bladder cancer
by: Kiltie, A, et al.
Published: (2018)

High levels of patient satisfaction in joint uro-oncology clinics to assist patient choice in early prostate cancer and muscle-invasive bladder cancer
by: Kiltie, A, et al.
Published: (2018)

Tumor markers of bladder cancer : the schistosomal bladder tumors versus non-schistosomal bladder tumors.
by: Abdulamir, Ahmed Sahib, et al.
Published: (2009)

Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center: In regard to Kotwal et al. - In reply to Dr. Rosario et al.
by: Kiltie, A, et al.
Published: (2008)

Predictive Biomarkers for Gemcitabine as a Chemoradiosensitizer in Bladder Cancer
by: Kerr, M, et al.
Published: (2012)

Numerical Study of Effects of Bladder Filling on Prostate Positioning In Radiotherapy
by: Krywonos, J, et al.
Published: (2009)

p97/VCP inhibition causes excessive MRE11-dependent DNA end resection promoting cell killing after ionizing radiation
by: Kilgas, S, et al.
Published: (2021)

Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer: Interventional procedures guidance [IPG628]
by: National Institute for Health and Care Excellence, CA, et al.
Published: (2018)